Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Amgen Inc.'s published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $236.4B | |
|---|---|---|
| Revenue (ttm) | 38.1B | |
| Net income (ttm) | 8.7B | |
| EPS (ttm) | $16.1 | |
| Shares out | 540.6M | |
| P/E (trailing) | 28.1x | |
| P/E (forward) | 18.2x | |
| Dividend | $10.1 (2.23%) | |
| Volume | 2,016,147 | |
| Beta | 0.41 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $25.98B | $26.32B | $28.19B | $33.42B | $36.75B | +9.1% |
| Gross profit | $19.53B | $19.92B | $19.74B | $20.57B | $26.01B | +7.4% |
| Operating income | $7.64B | $9.57B | $7.90B | $7.26B | $9.08B | +4.4% |
| Net income | $5.89B | $6.55B | $6.72B | $4.09B | $7.71B | +7.0% |
| EPS (diluted) | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 | +8.5% |
| EBITDA | $11.30B | $12.17B | $7.90B | $13.36B | $16.90B | +10.6% |
| R&D | $6.32B | $4.43B | $4.78B | $5.96B | $6.97B | +2.5% |
| SG&A | $5.37B | $5.41B | $6.18B | $7.10B | $7.05B | +7.1% |
Recent company headlines from major financial publishers.
Moderate growth and continued cash backing support the central valuation outlook. Evidence should emerge by FY2027 through annual revenue and adjusted EPS delivery.
Stronger revenue, earnings, and cash would extend growth duration without requiring a hyper-growth assumption. A low-end FY2027 earnings result would disconfirm this path.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.6% | $582 | $623 | $679 | $763 | $906 |
| 6.6% | $509 | $532 | $561 | $599 | $651 |
| 7.6% | $461 | $475 | $492 | $513 | $540 |
| 8.6% | $426 | $435 | $447 | $460 | $476 |
| 9.6% | $399 | $406 | $414 | $423 | $433 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
